Pictured: L-R - Charles Cornish (Chief Executive Officer) and Robert McLeay PhD (Founder & Chief Scientific Officer)
Digital health - leveraging technology to monitor and provide health-related data about individuals - is fast becoming a critical enabler of precision medicine. Cutting across the MTP and ICT sectors, digital health is driving an evolution in healthcare spanning prevention, diagnostics, therapeutics, management and cure. It is also impacting workforce capability, research, education, clinical tools and services.
With such rich potential to deliver better health outcomes for Australians, MTPConnect is a proud supporter of ANDHealth - Australia's only national digital health accelerator - and its work with mid-stage digital health companies.
One such company is DoseMe which is developing a precision dosing platform.They were selected from over 50 companies to participate in ANDHealth's first cohort and have utilised the program to drive and inform its US market entry strategy.
DoseMe's platform - DoseMeRx - is designed for clinicians at the point-of-care by using readily available patient data. Using this platform, clinicians can make real-time decisions on a patient's medication dosage and provide support from just one blood sample. DoseMeRx virtually constructs a model of each patient's individual pharmacokinetics. This allows clinicians to predict the optimal dose of medication, taking away the clinicians guess work and manual calculations.
The ANDHealth+ program assists Australian mid-stage digital health companies to meet key investor, partner and customer requirements around clinical and commercial validation by contributing AUD$60,000 to securing relevant third-party expertise, advice from a bespoke advisory panel and over $200,000 worth of in-kind offerings including technical platform services, media & communications, insurance, human resources, intellectual property and legal support.
Chief Executive Officer of DoseMe Charles Cornish says ANDHealth's process is unique.
"Unlike many accelerators and grants which focus on very early stage ideas, ANDHealth supports innovative companies like DoseMe to expand into other marketplaces and sustain that growth," Mr Cornish explained.
"Developing a strategy for DoseMe in partnership with a talented set of ANDHealth advisors, with expertise ranging from clinical research through to pharmaceutical marketing, is incredibly valuable as we continue to scale our operations."
DoseMe has made considerable commercial progress throughout their participation in the ANDHealth+ program. The company has successfully expanded their operations in both Australia, the United States, South Africa, the United Kingdom, Portugal, Brazil, Slovenia and Italy.
Managing Director and Co-Founder of ANDHealth Bronwyn Le Grice says the ANDHealth+ program has provided its cohort with great opportunities and exposure to new markets.
"ANDHealth was established to help companies just like DoseMe," Ms Le Grice added.
"By working closely alongside Charles and his team, the ANDHealth panel were able to provide key insights and deliver key pieces of work which directly contributed to the company's ability to scale internationally."
The DoseMeRx platform was ranked in the top 20 2018 Hot Apps for healthcare providers by Health Data Management. They also developed and validated a SMART-on-FHIR application available in both Cerner and Epic App stores.
For more information visit DoseMe.